COVID-19 and herd immunity.
作者信息
Ashton John
机构信息
Independent Public Health Consultant, Liverpool L25 5JF, UK.
出版信息
J R Soc Med. 2022 Feb;115(2):76-77. doi: 10.1177/01410768221080824.
Abstract
摘要
相似文献
1
COVID-19 and herd immunity.新冠病毒肺炎与群体免疫
J R Soc Med. 2022 Feb;115(2):76-77. doi: 10.1177/01410768221080824.
2
The long road.漫长的道路。
Science. 2021 Feb 19;371(6531):768-772. doi: 10.1126/science.371.6531.768.
3
Could COVID-19 be contained in poor populations by herd immunity rather than by strategies designed for affluent societies or potential vaccine(s)?新冠病毒肺炎能否通过群体免疫而非为富裕社会或潜在疫苗设计的策略在贫困人口中得到控制？
Glob Health Action. 2021 Jan 1;14(1):1863129. doi: 10.1080/16549716.2020.1863129.
4
Neutralizing SARS-CoV-2.中和 SARS-CoV-2
Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.
5
Mix-and-match COVID vaccines: the case is growing, but questions remain.混合搭配新冠疫苗：相关案例在增加，但问题依然存在。
Nature. 2021 Jul;595(7867):344-345. doi: 10.1038/d41586-021-01805-2.
6
COVID-19 pandemic and vaccination build herd immunity.新冠疫情及疫苗接种构筑群体免疫。
Eur Rev Med Pharmacol Sci. 2021 Jan;25(2):577-579. doi: 10.26355/eurrev_202101_24613.
7
The bumpy road to achieve herd immunity in COVID-19.实现 COVID-19 群体免疫的崎岖道路。
J Immunoassay Immunochem. 2020 Nov 1;41(6):928-945. doi: 10.1080/15321819.2020.1833919. Epub 2020 Oct 21.
8
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?接受BNT162b2 mRNA疫苗或AZD1222疫苗的健康志愿者中针对SARS-CoV-2的中和抗体反应比较：AZD1222疫苗的第二剂是否应提前接种？
Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.
9
Why scientists worldwide are watching UK COVID infections.为何全球科学家都在关注英国的新冠感染情况。
Nature. 2021 Nov;599(7884):189-190. doi: 10.1038/d41586-021-03003-6.
10
Can immune responses predict which vaccines work best?免疫反应能否预测哪些疫苗效果最佳？
Science. 2021 Jul 9;373(6551):142-143. doi: 10.1126/science.373.6551.142.
引用本文的文献
1
Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings.加拿大社区环境中 COVID 治疗适应性平台试验（CanTreatCOVID）：社区环境中急性 SARS-CoV-2 感染治疗随机对照适应性平台试验方案
BMJ Open. 2025 Aug 3;15(8):e097134. doi: 10.1136/bmjopen-2024-097134.
2
Lessons learned from COVID-19 and the implications for resilience research, policy and practice.从新冠疫情中吸取的教训及其对恢复力研究、政策和实践的启示。
J Conting Crisis Manag. 2022 Sep;30(3):226-230. doi: 10.1111/1468-5973.12413. Epub 2022 Aug 23.
3
Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection.冠状病毒刺突蛋白中保守区域对研发抗SARS-CoV-2感染新型疫苗的意义
Vaccines (Basel). 2023 Feb 24;11(3):545. doi: 10.3390/vaccines11030545.
4
Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave.在奥密克戎疫情浪潮之前，我们在希腊高、低 SARS-CoV-2 背景下关于血清流行率的经验教训。
Int J Environ Res Public Health. 2022 May 17;19(10):6110. doi: 10.3390/ijerph19106110.
5
99.53% and the history of probability.99.53%以及概率的历史。
J R Soc Med. 2022 Feb;115(2):45. doi: 10.1177/01410768221081358.
Zotero 插件